Full Text
Full text is available in PDF
Introduction:
Cutaneous leishmaniasis is endemic in Iran. Fasa region (Southern west of Iran) is one of the hot spots. The most popular drug for treatment of cutaneous leishmaniasis is glucantime.
Therapeutic and Adverse Effects of Glucantime Used for Treatment of Cutaneous Leishmaniasis.
Authors
+Corresponding Author: Clinic Number 1, Fasa Medical School, Fasa, Iran., [email protected]. Tel: +98 (917)112-1688. Email: [email protected]
Published online:Oct 01, 2007
Article type:Research Article
Received:Jun 01, 2007
Accepted:Aug 12, 2007
How to Cite:Beheshti M. Therapeutic and Adverse Effects of Glucantime Used for Treatment of Cutaneous Leishmaniasis.. Shiraz E-Med J. 2007;8(4):. doi:
Abstract
Aim:
To study the therapeutic and adverse effects of Glucantime in cutaneous leishmaniasis patients and also comparing the intramuscular and intralesional administration routes.
Materials and Methods:
All new cutaneous leishmaniasis cases (880) that were diagnosed within two years of study were ruled in. Intralesional injection was used for solitary nonfacial wounds, for maximum of 10 doses, injected every other day. For multiple lesions or facial lesions, intramuscular injection was performed, in daily manner for maximum of three 10 day periods, apart by 10 days of drug free intervals. Injections were done according to WHO guidelines.
Results:
The recovery rate was 84.03 % and 75.98% in intramuscular and intralesional injection groups, respectively. The most common side effect was skin hypersensitivity and urticaria, which was more seen in those with intralesional injection (10.92% in comparison with 2.59% in IM group). No cardiac or renal complication was observed.
Conclusion:
Complete recovery is higher in intramuscular injection compared to intralesional injection of Glucantime for cutaneous leishmaniasis. Side effects are also less seen in the intramuscular injection.
Highlights
Copyright
© 2007, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
6
Sep
2021
Comparative Assessment of Topical Glucantime® Injection Plus Cryotherapy and Cryotherapy Alone for Treatment of Anthroponotic Cutaneous Leishmaniasis
Mohammad Reza Shirzadi,
Amir Hamta,
Leyli Zanjirani Farahani,
Abedin Saghafipour,
Sadegh Rahi
Shirzadi MR, Hamta A, Zanjirani Farahani L, Saghafipour A, Rahi S. Comparative Assessment of Topical Glucantime® Injection Plus Cryotherapy and Cryotherapy Alone for Treatment of Anthroponotic Cutaneous Leishmaniasis. Arch Clin Infect Dis. 2021;16(3):e112222. doi: https://doi.org/10.5812/archcid.112222
30
Apr
2010
Intralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasis
Mohammad Ali Mapar,
Mohammad Omidian,
Mapar MA, Omidian M, . Intralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasis. Jundishapur J Microbiol. 2010;3(2):. doi:
20
Nov
2010
A Comparative Study of Aminosidine Sulfate, Meglomine Antimoniate, Combination of both and Glucantime in Murine Leishmaniasis Treatment of Cutaneous Leishmaniasis, Caused by Leishmania tropica, with Topical Application of Paromomycin 20% in BALB-c Mice
Mohammad Shahidi Dadras,
Afshin Mirzaei,
Bahram Kazemi,
Leyla Nabai,
Ali Sharifian
Shahidi Dadras M, Mirzaei A, Kazemi B, Nabai L, Sharifian A. A Comparative Study of Aminosidine Sulfate, Meglomine Antimoniate, Combination of both and Glucantime in Murine Leishmaniasis Treatment of Cutaneous Leishmaniasis, Caused by Leishmania tropica, with Topical Application of Paromomycin 20% in BALB-c Mice. Iran J Pharm Res. 2022;6(3):e128334. doi: https://doi.org/10.22037/ijpr.2010.723
25
Nov
2022
Epidemiological Study of Cutaneous Leishmaniasis in the Population Covered by Shahid Beheshti University of Medical Sciences in Iran from 2011 to 2021
Hossein Hatami,
Ali Ramezankhani,
Elham Hasannezhad,
Alireza Souri
Hatami H, Ramezankhani A, Hasannezhad E, Souri A. Epidemiological Study of Cutaneous Leishmaniasis in the Population Covered by Shahid Beheshti University of Medical Sciences in Iran from 2011 to 2021. Int J Infect. 2022;9(4):e123990. doi: https://doi.org/10.5812/iji-123990
25
Jul
2015
Epidemiological Aspects of Cutaneous Leishmaniasis in Iran
Salman Khazaei,
Abdollah Mohammadian Hafshejani,
Mohammad Saatchi,
Hamid Salehiniya,
Shahrzad Nematollahi
Khazaei S, Mohammadian Hafshejani A, Saatchi M, Salehiniya H, Nematollahi S. Epidemiological Aspects of Cutaneous Leishmaniasis in Iran. Arch Clin Infect Dis. 2015;10(3):e28511. doi: https://doi.org/10.5812/archcid.28511
Cited by
- Scopus by DOI: 0
Last Update: 1 month ago
- Scopus by Title: 0
Last Update: 1 month ago
- Scopus by Title (Ref): 14
Last Update: 1 month ago
- CrossRef: 0
Last Update: 2 days ago
Comments
Number of Comments:0